1. Scrip

M&A Values Continued To Decline During Q4 2024

 
• By Joseph Haas

Evaluate data show that the biopharma industry made $9.5bn of acquisitions during the fourth quarter, a third consecutive quarter of decline, although deal volume rose to 33 from Q3’s 29.

M&A
Biopharma M&A valuation was down substantially during the fourth quarter compared to Q4 2023 • Source: Shutterstock

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported that there were 33 M&A deals during Q4, up from 29 in the third quarter, but with a total valuation of slightly more than $9.5bn, down substantially from nearly $52.3bn in Q4 2023.

Industry watchers were ready with their explanations of why M&A activity had cratered throughout 2024 when positive conditions appeared...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.